FANCA and glioblastoma: Pertinent to the treatment of GBM, the FA pathway is activated in response to alkylating agents such as Temozolomide (TMZ) and Carmustine (BCNU; [18]), and previous work has demonstrated that FA-deficient cells are more sensitive to TMZ and BCNU than FA-proficient cells [18, 19].